熱門資訊> 正文
Ekso Bionics展示了外骨骼设备的AI集成突破
2025-06-18 20:12
- Ekso Bionics (NASDAQ:EKSO) on Wednesday said that it has successfully demonstrated initial proof-of-concept in integrating artificial intelligence-enabled capabilities across its portfolio of enterprise health and personal health exoskeleton devices.
- The first of these capabilities is a new AI voice agent designed for intelligent control of the company’s legacy EksoNR device.
- Ekso Voice Agent is being implemented on NVIDIA (NVDA) Jetson Orin Nano hardware developed with the NVIDIA JetPack SDK and OpenAI tools for voice recognition.
- The proof-of-concept is configured as an Edge AI system, which can run with or without a connection to the cloud.
More on Ekso Bionics Holdings
- Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript
- Ekso Bionics announces 1-for-15 reverse stock split
- Ekso bionics anticipates scaling personal health revenues in 2025 with new partnerships
- Seeking Alpha’s Quant Rating on Ekso Bionics Holdings
- Historical earnings data for Ekso Bionics Holdings
推薦文章
一周財經日曆丨降息信號將定？下周全球央行年會成關鍵；小米、泡泡瑪特、快手領銜港股財報潮
港股周報丨見證歷史！南向資金單日瘋狂買入港股359億港元；騰訊績后股價一度升破600港元
特朗普政府據悉考慮動用芯片法案資金來入股英特爾
美股機會日報丨「恐怖數據」符合預期，交易員下調美聯儲降息預期；巴菲特Q2新建倉股飆升，聯合健康盤前漲超10%
銀諾醫藥-B上市首日暴漲285%，一手賺超1萬港元
投資大佬Tepper減持阿里巴巴、京東等 買入股價暴跌的聯合健康
伯克希爾減持蘋果股份 增持聯合健康集團
8月15日外盤頭條：特朗普政府洽購英特爾股份 貝森特否認推動降息 蘋果重新設計Apple Watch血氧功能
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
